Reply to Dr Boers’ letter

Sir,

The communication by Boers reacts to my reply to Dr Yazici (1), who claimed that some secondary outcomes in the paper Anakinra for Colchicine-Resistant Familial Mediterranean Fever… (2) might be type 1 error (related to the finding that anakinra suppresses FMF-joint attacks \(p=0.019\)) and type 2 error, (related to the finding that anakinra did not suppress the abdominal attacks \(p=0.38\)). At that time, I thought that one must view the null hypothesis, before suggesting type 1 or type 2 errors (because type 1 and type 2 errors rely on the null hypothesis), but I was wrong. Statistical inference always bears the possibility that the conclusion might be incorrect. The whole idea behind the p-value is to determine the level of error if the null hypothesis is correct. In this respect, Dr. Yazici’s claim is not different from a general notion that despite the significance or insignificance of the p-value, there is still room for possible inference mistake. The same concern applies for any new drug or device tested for performance, founding its effectiveness based on the p-value obtained from the test, and submitted for regulatory approval. I do not see any reason to discuss this matter specifically for the anakinra paper.

A. Livneh, MD

Department of Medicine 6, Sheba Medical Centre, Tel Hashomer, Israel.

Please address correspondence to:
Dr. Avi Livneh,
Department of Medicine 6, Sheba Medical Centre, 52650 Tel Hashomer, Israel.
E-mail: alivneh@post.tau.ac.il

© Copyright CLINICAL AND EXPERIMENTAL RHUMATOLOGY 2017.
Competing interests: The Anakinra study was supported by a grant from Sobi.

References